Astria Therapeutics (NASDAQ:ATXS) Stock Price Up 5.5% – Here’s Why

Astria Therapeutics, Inc. (NASDAQ:ATXS) rose 5.5% on Wednesday . The company traded as high as $10.73 and last traded at $10.72. Approximately 431,898 shares were traded during mid-day trading, a decline of 27% from the average daily volume of 594,279 shares. The stock had previously closed at $10.16.

Wall Street Analyst Weigh In

Several research firms have weighed in on ATXS. Oppenheimer raised their price target on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Tuesday. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Astria Therapeutics presently has an average rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Trading Down 3.4 %

The stock has a fifty day moving average of $10.87 and a two-hundred day moving average of $10.68.

Institutional Investors Weigh In On Astria Therapeutics

A number of hedge funds have recently made changes to their positions in ATXS. Quest Partners LLC raised its position in Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 3,112 shares during the period. PDT Partners LLC bought a new stake in shares of Astria Therapeutics in the 3rd quarter valued at about $140,000. SG Americas Securities LLC purchased a new stake in Astria Therapeutics during the 3rd quarter valued at about $155,000. Price T Rowe Associates Inc. MD purchased a new stake in Astria Therapeutics during the 1st quarter valued at about $200,000. Finally, Hsbc Holdings PLC bought a new position in Astria Therapeutics during the 2nd quarter worth approximately $171,000. 98.98% of the stock is currently owned by institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.